Market Access VCs upbeat about European life sciences market, despite unce... It has been a curious start to the year for pharma and biotech investment.
News UK's long-term R&D investment policy welcomed The decision by the UK to set new 10-year budgets for public R&D funding has received a positive response from academia and the pharma industry.
News RFK Jr defends HHS cuts, measles stance in Congress hearings HHS Secretary Robert F Kennedy Jr would not explicitly endorse measles vaccines at Congressional hearings, and deflected questions on department cuts.
News EU joins the bid to court beleaguered US scientists The EU has announced a €500m scheme to convince scientific talent from around the world to relocate to Europe's "free and open" research environment.
News Can other countries entice US scientists hit by Trump cuts? The UK is said to be preparing a £50m scheme to attract top scientific talent from other countries, including US teams facing big funding cuts.
News Trump's budget would be "catastrophic" for federal R&D Trump's 2026 budget request envisages sweeping cuts to funding for the NIH and other federal agencies that will be a disaster, say science advocates.
Oncology Treating primary bone cancer: The potential of listeria-base... In a new pharmaphorum podcast, Paul Romness, president and CEO of OS Therapies, discusses the company's work in osteosarcoma.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face
